GenVec, Inc.

(Public, NASDAQ:GNVC)

StocksHaven Investments profiles a clinical stage biopharmaceutical company developing gene-based therapeutic drugs and vaccines. Its lead product candidate, TNFerade biologic (TNFerade), is being developed for use in the treatment of cancer, and is currently undergoing Phase III trials which are expected to be completed by Q1 2010. In addition to its therapeutic product development programs, GenVec is working with collaborators to develop new applications for its technology through its vaccine development programs. The Company is developing a vaccine in animal health against foot-and-mouth disease and preventative vaccines for malaria, human immunodeficiency virus (HIV), respiratory syncytial virus, and Herpes Simplex Virus Type 2 (HSV-2). Surrounded by cash infusions through grants, mutual and institutional investors, multi-purpose products with billion dollar market potential, and an already flowing revenue stream – GenVec is one company you shouldn’t pass by.

About

Genvec

...

by Manuel Alvarez-Rivera, Puerto Ricobr /br /Just two years after holding a A HREF="http://globaleconomydoesmatter.blogspot.com/2007/05/iceland-2007-parliamentary-election.html"parliamentary election/A, voters in Iceland are likely to return to the polls next May 9 for an early general election. Normally, the poll would not need to be held until 2011, but these are anything but normal times in the Nordic island nation, whose economy has been devastated by the ongoing global financial crisis.br /br /With all of Iceland's three major banks under receivership since October; the national currency (the krona) having lost over half its value and the stock market over 90 percent of its value; inflation and unemployment on the rise; and the GDP expected to contract by ten percent this year, public discontent over the perceived mismanagement of the economy by the coalition government of Iceland's two major parties - the conservative Independence Party and the left-of-center Social Democratic Alliance - has fueled mounting ...

October 15 - SpectraScience (OTCBB: SCIE) has made several announcements over the past month which signal key milestones in its plan to accelerate out of R&D for its cancer screening platforms and into wide-scale sales. September 16 - delivered WavSTAT® Optical Biopsy System to the Mayo Clinic and University of California at San Diego/VA to complete studies demonstrating the clinical value of the system as a means of improving screening for esophageal cancer; October 1 - delivered WavSTAT Optical Biopsy System to the University of Southern California for similar tests; and October 2 - awarded patent in Canada for its WavSTAT Optical Biopsy System. SpectraScience holds about 60 patents globally for its WavSTAT and LUMA® Cervical Imaging Systems. We have previously written about the real need for a better screening device to detect esophageal cancer, and that the incidence of adenocarcinoma of the esophagus has increased steadily in white Americans over the past 30 years, at a 335% increase in incidence rates amongst ...